Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension

Objective: Adding selexipag to the combined treatment of endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitor (PDE5i) reduces the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH) but at a considerably higher cost. This study evaluated the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Wenxing, Zhang, Zhe, Chu, Mingming, Gu, Peng, Hu, Min, Liu, Lulu, Huang, Jingbin, Zhang, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456866/
https://www.ncbi.nlm.nih.gov/pubmed/37637431
http://dx.doi.org/10.3389/fphar.2023.1122866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456866/
https://www.ncbi.nlm.nih.gov/pubmed/37637431
http://dx.doi.org/10.3389/fphar.2023.1122866

Ejemplares similares